Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced the pricing of an underwritten public offering of 5,714,283 shares at $0.70 per share, aiming to raise approximately $4 million in gross proceeds.
The company plans to allocate $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital. WestPark Capital is serving as the Sole Book-Runner, with the offering expected to close on July 25, 2025.
iSpecimen (Nasdaq: ISPC), un mercato online di biospecimen, ha annunciato il prezzo di un'offerta pubblica sottoscritta di 5.714.283 azioni a 0,70 $ per azione, con l'obiettivo di raccogliere circa 4 milioni di dollari di proventi lordi.
L'azienda prevede di destinare 1,5 milioni di dollari per servizi di marketing tramite IR Agency LLC, 1 milione di dollari per un pagamento iniziale legato a un traguardo a Sales Stack Solutions Corp., e il resto per il capitale operativo. WestPark Capital agisce come unico bookrunner, con la chiusura dell'offerta prevista per il 25 luglio 2025.
iSpecimen (Nasdaq: ISPC), un mercado en línea de biospecímenes, ha anunciado el precio de una oferta pública suscrita de 5,714,283 acciones a
La compañía planea destinar 1.5 millones de dólares para servicios de marketing a través de IR Agency LLC, 1 millón de dólares para un pago inicial por hitos a Sales Stack Solutions Corp., y el resto para capital de trabajo. WestPark Capital actúa como único bookrunner, y se espera que la oferta cierre el 25 de julio de 2025.
iSpecimen (나스닥: ISPC)는 바이오시료 온라인 마켓플레이스이며, 5,714,283주를 주당 0.70달러에 인수 공모 가격을 책정하여 약 400만 달러의 총 수익을 목표로 한다고 발표했다.
회사는 IR Agency LLC를 통한 마케팅 서비스에 150만 달러, Sales Stack Solutions Corp.에 대한 초기 마일스톤 지급금으로 100만 달러를 배정하고 나머지는 운전자본으로 사용할 계획이다. WestPark Capital이 단독 주관사로 활동하며, 공모는 2025년 7월 25일에 마감될 예정이다.
iSpecimen (Nasdaq : ISPC), une place de marché en ligne pour les biospécimens, a annoncé le prix d'une offre publique souscrite de 5 714 283 actions à 0,70 $ par action, visant à lever environ 4 millions de dollars de produit brut.
La société prévoit d'allouer 1,5 million de dollars aux services marketing via IR Agency LLC, 1 million de dollars à un paiement initial lié à un jalon à Sales Stack Solutions Corp., et le reste pour le fonds de roulement. WestPark Capital agit en tant que teneur de livre unique, avec une clôture de l'offre prévue pour le 25 juillet 2025.
iSpecimen (Nasdaq: ISPC), ein Online-Marktplatz für Biospezimen, hat die Preisfestsetzung eines unterzeichneten öffentlichen Angebots von 5.714.283 Aktien zu 0,70 $ pro Aktie bekannt gegeben, mit dem Ziel, rund 4 Millionen US-Dollar Bruttoerlös zu erzielen.
Das Unternehmen plant, 1,5 Millionen US-Dollar für Marketingdienstleistungen über IR Agency LLC, 1 Million US-Dollar für eine anfängliche Meilensteinzahlung an Sales Stack Solutions Corp. und den Rest für das Betriebskapital zu verwenden. WestPark Capital fungiert als alleiniger Bookrunner, und der Abschluss des Angebots wird für den 25. Juli 2025 erwartet.
- Expected to raise $4 million in gross proceeds
- Firm commitment basis offering provides funding certainty
- Strategic allocation of funds for marketing and sales initiatives
- Significant dilution for existing shareholders at $0.70 per share
- 62.5% of proceeds already earmarked for specific payments, leaving limited working capital
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced on July 24, 2025 the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of
The Company intends to use the net proceeds from the Offering to pay
The Offering is being conducted on a firm commitment basis. WestPark Capital, Inc. acted as the Sole Book-Runner in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-286958), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 23, 2025. The Offering is being made only by means of a written prospectus that forms a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC. When available, copies of the final prospectus relating to the Offering may be obtained from WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90077, tel: 310-203-2919, e-mail: jstern@wpcapital.com and will be available on the SEC’s website.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company’s ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
FAQ
What is the size and price of iSpecimen's (ISPC) July 2025 offering?
How will iSpecimen (ISPC) use the proceeds from its $4M offering?
Who is the underwriter for iSpecimen's (ISPC) July 2025 offering?
When is iSpecimen's (ISPC) $4M offering expected to close?
What type of securities is iSpecimen (ISPC) offering in July 2025?
